Home Drug Development Products Decapeptyl®, Neo Decapeptyl®…

Decapeptyl®, Neo Decapeptyl®, Trelstar®, Pamorelin®, Triptodur®

Triptorelin is a gonadotropin releasing hormone (GnRH) agonist

Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur®, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castration levels (estradiol in females).

Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the quality of life of patients. GnRH agonist treatment achieves similar overall survival rates in advanced prostate cancer as surgical castration. The triptorelin 1-month, 3-month and 6-month sustained release formulations have provided patients with a convenient treatment modality.

In short

GnRH was discovered by Professor Andrew Schally (1971 - Tulane University), who co-received the Nobel Prize in 1977 for his discovery. He performed the first synthesis of the GnRH agonist triptorelin in 1973.

In 2023, triptorelin was the 2nd best selling Ipsen oncology drug

Product Overview

Indications

  • Advanced prostate cancer
  • Endometriosis
  • In-vitro fertilization programs
  • Uterine fibroids
  • Central precocious puberty

Product Characteristics

3 dosages:

  • 1-month (3.75 mg)
  • 3-month (11.2 mg)
  • 6-month (22.5 mg)

Debiopharm's Added Value

  • Development and registration of the triptorelin 1-, 3- and 6-month sustained release formulations around the world.
  • Continuous life-cycle management (new formulations, route of administration, indications)
  • First worldwide registered sustained release formulation of a gonadotropin releasing hormone (GnRH) agonist in 1986.

Commercial map

Aché Laboratórios Farmacêuticos SA
  • Brazil
More info
Verity Pharmaceuticals Inc.
  • United States
More info
Azurity Pharmaceuticals
  • United States
More info
Dr. Reddy's Laboratories
  • India
More info
Ferring International Center
  • Israel
More info
Ipsen Pharma
  • Algeria
  • Andorra
  • Australia
  • Austria
  • Belarus
  • Belgium
  • China
  • Cyprus
  • Costa Rica
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Estonia
  • Finland
  • France
  • Monaco
  • French Guiana
  • French Polynesia
  • Georgia
  • Germany
  • Greece
  • Guadeloupe (France)
  • Hong Kong
  • Hungary
  • Iraq
  • Iran
  • Ireland
  • Italy
  • Jordan
  • Kazakhstan
  • Kuwait
  • Latvia
  • Lebanon
  • Lithuania
  • Luxembourg
  • Madagascar
  • Martinique (France)
  • Mauritius
  • Morocco
  • Mayotte (France)
  • Netherlands
  • New Zealand
  • New Caledonia
  • Norway
  • Poland
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Montenegro
  • Slovakia
  • Slovenia
  • South Korea
  • Spain
  • Sweden
  • Tunisia
  • Ukraine
  • Uzbekistan
  • Vietnam
  • Wallis and Futuna (France)
  • United Kingdom
  • United Arab Emirates
  • Saudi Arabia
  • Thailand
More info
Orient Europharma
  • Malaysia
  • Singapore
  • Taiwan
More info
Adium
  • Argentina
  • Bolivia
  • Chile
  • Colombia
  • Ecuador
  • Mexico
  • Paraguay
  • Peru
  • Uruguay
  • Venezuela
More info
Unilab
  • Philippines
More info
Debiopharm
  • Switzerland
More info
KNIGHT THERAPEUTICS INC.
  • Canada
More info
Dexa Medica
  • Indonesia
More info
Aspen
  • South Africa
More info

Press Releases

All triptorelin related press releases

Selected Publications

All triptorelin related publications